Cargando…

Different Modes of Cell‐killing Action between DNA Topoisomerase I and II Inhibitors Revealed by Kinetic Analysis

We compared the modes of cell‐killing by DNA topoisomerase I and II inhibitors. The effects of camptothecin (CPT), KT‐6528 and UCE6 upon colony formation by inhibiting DNA topoisomerase I, and of etoposide (VF‐16), teniposide, amsacrine and UCT4‐A as inhibitors of DNA topoisomerase II were analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inaba, Makoto, Mitsuhashi, Junko, Kawada, Shouzou, Nakano, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1994
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919418/ https://www.ncbi.nlm.nih.gov/pubmed/8144400 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02081.x

Ejemplares similares

Kinetic Analysis of 5‐Fluorouracil Action against Various Cancer Cells
por: Inaba, Makoto, et al.
Publicado: (1990)

Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition
por: Nishida, Masahiro, et al.
Publicado: (2022)

Potentiation of Topoisomerase I and II Inhibitors Cell Killing by Tumor Necrosis Factor: Relationship to DNA Strand Breakage Formation
por: Orengo, Giorgia, et al.
Publicado: (1992)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
por: Barker, Catherine R., et al.
Publicado: (2006)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
por: Twelves, C J, et al.
Publicado: (1999)

Kinetic pathways of topology simplification by Type-II topoisomerases in knotted supercoiled DNA
por: Ziraldo, Riccardo, et al.
Publicado: (2019)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Optimization of the Lactam Side Chain of 7-Azaindenoisoquinoline Topoisomerase I Inhibitors and Mechanism of Action Studies in Cancer Cells
por: Kiselev, Evgeny, et al.
Publicado: (2014)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae
por: Foerster, Sunniva, et al.
Publicado: (2015)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
por: Xu, Huanli, et al.
Publicado: (2016)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

Inhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II
Publicado: (1992)

DNA topoisomerase I and II expression in drug resistantgerm cell tumours
por: Berney, D M, et al.
Publicado: (2002)

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
por: Vasey, P. A., et al.
Publicado: (1997)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks
por: Dauda, Soziema E., et al.
Publicado: (2023)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes
por: Chae, Sieun, et al.
Publicado: (2018)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Inhibition of Topoisomerase II by a Novel Antitumor Cyclic Depsipeptide, BE‐22179
por: Yoshinari, Tomoko, et al.
Publicado: (1994)

Lapcin, a potent dual topoisomerase I/II inhibitor discovered by soil metagenome guided total chemical synthesis
por: Wang, Zongqiang, et al.
Publicado: (2022)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

Single-molecule analysis uncovers the difference between the kinetics of DNA decatenation by bacterial topoisomerases I and III
por: Terekhova, Ksenia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5hv5pfncnt7iiqqd5mfkoal6m7